《全球十大体外诊断公司-英文提纲.doc》由会员分享，可在线阅读，更多相关《全球十大体外诊断公司-英文提纲.doc（11页珍藏版）》请在金锄头文库上搜索。
1、全球十大体外诊断公司：定位，性能及SWOT分析报告2009/09/23 22:48The Top Ten Global In-Vitro Diagnostics Companies: Positioning, performance and SWOT analyses摘要The in-vitro diagnostics (IVD) market continues to grow at a steady pace, driven by new fields such as molecular diagnostics and the growing consumer awareness surr
2、ounding disease management. There is also an increasing focus on emerging markets, where healthcare infrastructures are continually improving. The industry is highly competitive and continues to witness large scale consolidation. Large in-vivo players are beginning to enter the in-vitro market and t
3、he regulatory environment is becoming even more stringent, increasing the time to get approvals for new products. the Top Ten Global In-Vitro Diagnostics Companies?is a new report published by Business Insights that that explores the global competitive landscape of the IVD industry. This report anal
4、yses the size and structure of the market and identifies the latest developments in service offerings, new technologies, strategic approaches and competitive dynamics amongst leading companies. This report assesses the opportunities and threats facing the top 10 IVD companies in the future, and exam
5、ines their current structure, financial performance, growth strategies and R&D activity. Growth forecasts for key products and regions are also provided.Published: March 2009 - Global.目录及图表Executive summary 16Market Development 16Roche Diagnostics 17 Siemens Healthcare 17 Abbott 18 J&J 19 Beckman Co
6、ulter 19 Becton Dickinson 20 bioMerieux 21 Bayer Diabetes 21 Sysmex 22 Bio Rad 23Chapter 1 Introduction 26What is this report about? 26Methodology and definitions 26Chapter 2 Market development 30Summary 30Overview 31Market size and growth 31Growth drivers 31Key trends in the market 32Industry conso
7、lidation 32Convergence of IVD and In-vivo 32Customer consolidation 33Emergence of theranostics 33Chapter 3 Roche Diagnostics 38Summary 38Company overview 39Group structure 39Professional Diagnostics 39Diabetes Care 39Molecular Diagnostics 40Applied Science 40Recent financial performance 40Performanc
8、e by business segments (IVD) 42Professional Diagnostics 42Diabetes Care 42Molecular Diagnostics 42Performance by geographies 43Acquisitions and divestments 44Research and Development 45Growth strategies 45SWOT analysis 46Strengths 46Dominant market position 46Diversified portfolio 47Strong R&D facil
9、ities 47Weaknesses 47Slow growth of molecular diagnostics business 47Opportunities 47Molecular diagnostics market 47Diabetes care and tissue diagnostics 48Threats 48Competition 48Customer consolidation 48Stringent regulations 49Chapter 4 Siemens Healthcare 52Summary 52Company overview 53Group struct
10、ure 53Recent financial performance 54Acquisitions and divestments 55Research and development 55Growth strategies 56SWOT analysis 57Strengths 57Full suite of diagnostics offering 57Strong market position 58Strong brand name 58Weaknesses 58Late entry into IVD 58Opportunities 58Integrated offerings 58M
11、olecular diagnostics market 59Threats 59Competition 59Regulation 59Chapter 5 Abbott 62Summary 62Company overview 63Group structure 63Recent financial performance 64Performance by products 65Performance by geographies 66Acquisitions and divestments 66Research and development 67Growth strategies 67SWO
12、T analysis 68Strengths 68Diversified revenue stream 68Strong performance of international diagnostics business 69Weaknesses 69Declining margins 69Regulatory issues 69Sluggish top line growth in the domestic market 69Opportunities 70Molecular diagnostics 70Diabetes care market 70Threats 70Competition
13、 70Regulatory environment 70Chapter 6 Johnson & Johnson 72Summary 72Company overview 73Group structure 73Ortho-Clinical Diagnostics 73Veridex 74LifeScan 74Recent financial performance 74Performance by businesses 75LifeScan 75Ortho-Clinical Diagnostics 75Veridex 76Acquisitions and divestments 76Growt
14、h strategies 77Strategic partnerships 77Acquisitions 77SWOT analysis 78Strengths 78Strong market position 78J&J brand 79Strong topline growth 79Weaknesses 79Small contribution to J&J revenues 79Opportunities 79Amic acquisition 79Diabetes monitoring market 80Threats 80Competition 80Regulations 80Chap
15、ter 7 Beckman Coulter (Beckman) 82Summary 82Company overview 83Group structure 83Clinical Diagnostics 84Recent financial performance 84Performance by geographies 85Acquisitions and divestments 87Research and Development 87Growth strategies 88Focus on immunoassay systems and molecular diagnostics 88Expansion into emerging markets 89SWOT analysis 89Strengths 90Global presence 90Strong market position 90Diverse product portfolio 90Strong performance of immunoassay systems 90
